ESMO速报：K药联合化疗治疗晚期三阴性乳腺癌；CAR-T疗法在实体瘤领域又迈一步？

编者按：

• 局部复发性不可手术或转移性TNBC患者还得靠化疗？K药联合化疗是更好选择！——LBA16-KEYNOTE-355:Final results from a randomized,double-blind phase III study offirst-line pembrolizumab+chemotherapy vs placebo+chemotherapy for metastatic TNBC

• 不止血液肿瘤！CAT-T疗法在难治性CLDN18.2+消化系统肿瘤患者中展现活性！——1372O-CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system

• 优于多西他赛单药治疗！多西他赛联合普那布林为晚期NSCLC二、三线治疗提供新选择！——LBA48-DUBLIN-3(BPI-2358-103):A Global Phase(Ph)3 Trial with the Plinabulin/Docetaxel(Plin/Doc)combination vs.Doc in 2nd/3rd Line NSCLC Patients(pts)with EGFR-wild type(wt)Progressing on a Prior Platinum-Based Regimen

本文首发：医学界肿瘤频道

本文作者：ESMO报道小组